Table 5. Univariate Analysis of Risk Factors for Currently Receiving Special Education Services, Factors p ≤ 0.10.
| Factor | Comparison Group | Reference Group | Odds Ratio |
p-value |
|---|---|---|---|---|
| Primary diagnosis | Other Cholestatic or Metabolic Fulminant liver failure Cirrhosis Other |
Biliary atresia | 1.54 1.01 0.63 1.27 |
p = 0.0448 |
| Growth Deficit at Tx |
Yes | No | 1.39 | p = 0.0477 |
| Immunosuppressio n at Tx |
Cyclosporine Other |
Tacrolimus | 1.72 0.63 |
p = 0.0057 |
| Immuno at 6 months post tx |
Cyclosporine Other |
Tacrolimus | 1.59 5.49 |
p = 0.0019 |
| Nutrition Intake at Listing |
Tube IV |
Mouth | 1.75 1.38 |
p = 0.0289 |
| Early use of monoclonal or polyclonal antibodies |
Yes | No | 1.41 | p = 0.0846 |
| Symptomatic CMV within 6 mths of Tx |
Yes | No | 2.15 | p = 0.0051 |
| PreTx Special Edu Needs |
Yes | No | 13.97 | p <0.0001 |
| Parent Highest Edu |
College or Above | Less than College | 0.70 | p = 0.0234 |
| Year of Tx | >=2002 | <=2001 | 0.72 | p = 0.0354 |
| Initial Hospital Stay |
Continuous Predictor | 1.01 | p = 0.0008 | |
| Log INR | Continuous Predictor | 0.75 | p = 0.0985 | |
| Change in weight z score at 6 months post Tx |
Continuous Predictor | 0.87 | p = 0.0600 | |